Premium
Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes
Author(s) -
Eftekhar Maryam,
Mirhashemi Elham S.,
Tabibnejad Nasim
Publication year - 2019
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.12707
Subject(s) - polycystic ovary , luteinizing hormone , infertility , medicine , pregnancy , pregnancy rate , anti müllerian hormone , gynecology , testosterone (patch) , in vitro fertilisation , embryo transfer , hormone , andrology , endocrinology , biology , insulin , insulin resistance , genetics
Objective To explore assisted reproductive outcomes among women with different polycystic ovary syndrome ( PCOS ) phenotypes. Methods A retrospective cohort study included women with PCOS who were treated at Yazd Research and Clinical Center for Infertility, Yazd, Iran, using the Gn RH antagonist protocol between April 1, 2015, and August 31, 2017. Clinical pregnancy was the primary outcome, and chemical pregnancy, implantation rate, fertilization rate, and spontaneous abortion rate, were the secondary outcomes that were evaluated among four defined phenotypes of women with PCOS . Results Significant differences were observed between the phenotypes for the levels of luteinizing hormone, anti‐Müllerian hormone, fasting blood sugar, and total testosterone concentration; similarly, the percentage of women with luteinizing hormone/follicle stimulating hormone ratio of at least 2.5 differed between PCOS phenotypes (all P <0.001). There were also significant differences in estradiol level ( P <0.001) and the number of matured follicles ( P =0.002) between different phenotypes. No significant differences were observed in the fertilization and implantation rates, as well as chemical and clinical pregnancy rates (all P >0.05). Conclusion No significant differences were observed in assisted reproductive technique outcome among women with different phenotypes of PCOS undergoing frozen‐thawed embryo transfer.